RARE
Price
$27.39
Change
-$0.15 (-0.54%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
2.65B
85 days until earnings call
SLNO
Price
$85.76
Change
+$3.41 (+4.14%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
4.38B
86 days until earnings call
Interact to see
Advertisement

RARE vs SLNO

Header iconRARE vs SLNO Comparison
Open Charts RARE vs SLNOBanner chart's image
Ultragenyx Pharmaceutical
Price$27.39
Change-$0.15 (-0.54%)
Volume$30.36K
Capitalization2.65B
Soleno Therapeutics
Price$85.76
Change+$3.41 (+4.14%)
Volume$56.92K
Capitalization4.38B
RARE vs SLNO Comparison Chart in %
Loading...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RARE vs. SLNO commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a StrongBuy and SLNO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (RARE: $27.54 vs. SLNO: $82.35)
Brand notoriety: RARE and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 71% vs. SLNO: 87%
Market capitalization -- RARE: $2.65B vs. SLNO: $4.38B
RARE [@Biotechnology] is valued at $2.65B. SLNO’s [@Biotechnology] market capitalization is $4.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNO is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 4 TA indicator(s) are bullish while SLNO’s TA Score has 5 bullish TA indicator(s).

  • RARE’s TA Score: 4 bullish, 5 bearish.
  • SLNO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SLNO is a better buy in the short-term than RARE.

Price Growth

RARE (@Biotechnology) experienced а -3.16% price change this week, while SLNO (@Biotechnology) price change was -4.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

RARE is expected to report earnings on Nov 04, 2025.

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($4.38B) has a higher market cap than RARE($2.65B). SLNO YTD gains are higher at: 83.204 vs. RARE (-34.538). SLNO has higher annual earnings (EBITDA): -194.63M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. SLNO (290M). RARE has less debt than SLNO: RARE (38.3M) vs SLNO (52.8M). RARE has higher revenues than SLNO: RARE (591M) vs SLNO (0).
RARESLNORARE / SLNO
Capitalization2.65B4.38B61%
EBITDA-449.9M-194.63M231%
Gain YTD-34.53883.204-42%
P/E RatioN/AN/A-
Revenue591M0-
Total Cash494M290M170%
Total Debt38.3M52.8M73%
FUNDAMENTALS RATINGS
RARE vs SLNO: Fundamental Ratings
RARE
SLNO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9341
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3634

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (74) in the Biotechnology industry is in the same range as SLNO (76) in the Medical Specialties industry. This means that RARE’s stock grew similarly to SLNO’s over the last 12 months.

SLNO's Profit vs Risk Rating (39) in the Medical Specialties industry is somewhat better than the same rating for RARE (100) in the Biotechnology industry. This means that SLNO’s stock grew somewhat faster than RARE’s over the last 12 months.

SLNO's SMR Rating (99) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that SLNO’s stock grew similarly to RARE’s over the last 12 months.

SLNO's Price Growth Rating (41) in the Medical Specialties industry is somewhat better than the same rating for RARE (93) in the Biotechnology industry. This means that SLNO’s stock grew somewhat faster than RARE’s over the last 12 months.

SLNO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that SLNO’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RARESLNO
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
69%
Bullish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 12 days ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCRX21.550.18
+0.84%
Loomis Sayles Small Cap Value Retail
JRASX91.330.58
+0.64%
Janus Henderson Research S
IOGYX41.290.14
+0.34%
Invesco Gold & Special Minerals R5
DNDGX19.77-0.10
-0.50%
Dunham Small Cap Growth N
PICMX61.69-1.20
-1.91%
Virtus KAR Mid-Cap Growth I

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-1.04%
MREO - RARE
65%
Loosely correlated
-3.16%
TRDA - RARE
46%
Loosely correlated
-2.08%
REPL - RARE
46%
Loosely correlated
N/A
NRIX - RARE
46%
Loosely correlated
-2.28%
IDYA - RARE
45%
Loosely correlated
+3.08%
More

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
+4.62%
SYRE - SLNO
42%
Loosely correlated
N/A
NKTX - SLNO
41%
Loosely correlated
-1.49%
RARE - SLNO
40%
Loosely correlated
-1.04%
CRNX - SLNO
39%
Loosely correlated
-3.69%
RVMD - SLNO
39%
Loosely correlated
+0.17%
More